Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | CLPP | Q16740 | 16/20 | 0.58 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1550311 | 0.90 | KDM4E (0.63) | KDM4EALDH1A1GLAGAAMAPT | |
| Hydrochloric Acid SCHEMBL3188334 | 0.88 | KDM4E (0.61) | KDM4EALDH1A1GLAGAAMAPT | |
| SCHEMBL2454865 | 0.88 | MAPT (0.51) | KDM4EALDH1A1GLAGAAMAPT | |
| SCHEMBL20214121 | 0.81 | KDM4E (0.49) | KDM4EALDH1A1GLAGAAMAPT | |
| SCHEMBL22214072 | 0.79 | GRIA1 (0.39) | KDM4EALDH1A1GLAGAAMAPT | |
| SCHEMBL14042325 | 0.79 | KDM4E (0.37) | KDM4EALDH1A1GLAGAAMAPT | |
| SCHEMBL4155645 | 0.79 | CLPP (0.58) | CLPPSLC6A5MEN1KMT2A | |
| SCHEMBL22915965 | 0.78 | ACHE (0.50) | KDM4EALDH1A1GLAGAAMAPT | |
| SCHEMBL3435800 | 0.77 | CLPP (0.68) | CLPPMEN1KMT2A | |
| SCHEMBL550151 | 0.76 | SIGMAR1 (0.50) | KDM4EALDH1A1GLAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630116-B1 | TETRAHYDROPYRIDO[4,3-D]PYRIMIDINE INHIBITORS OF ATR KINASE | UNIV TEXAS (US) | 2024-05-01 | — | — | EP | disclosed |
| US-10745420-B2 | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-08-18 | — | — | US | disclosed |
| US-10745420-B2 | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-08-18 | — | — | US | disclosed |
| US-10421765-B2 | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-09-24 | — | — | US | disclosed |
| US-10421765-B2 | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-09-24 | — | — | US | disclosed |
| US-20180370990-A1 | TETRAHYDROPYRIDO[4,3-d]PYRIMIDINE INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2018-12-27 | — | — | US | disclosed |
| EP-2376478-B1 | PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-04-19 | — | — | EP | disclosed |
| EP-2136639-B1 | PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2016-03-09 | — | — | EP | disclosed |
| EP-2136639-B1 | PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2016-03-09 | — | — | EP | disclosed |
| EP-1885369-B1 | FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2015-09-23 | — | — | EP | disclosed |
| WO-2008123963-A1 | PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008123963-A1 | PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| EP-1885369-A2 | FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | Renovis, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20060258689-A1 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | EVOTEC SE (DE) | 2006-11-16 | — | — | US | disclosed |
| WO-2006119504-A2 | FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006119504-A2 | FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| US-6414157-B1 | COMPOUNDS HAVING HIGH AFFINITY FOR 5-HT1B AND 5-HT1C SEROTONIN RECEPTOR; ANTIDEPRESSANTS | ABBOTT LABORATORIES | 2002-07-02 | — | — | US | disclosed |
| EP-1025100-B1 | 3-SUBSTITUTED TETRAHYDROPYRIDOPYRIMIDINONE DERIVATIVES, METHOD FOR PRODUCING THE SAME, AND THEIR USE | BASF AG (DE) | 2002-01-23 | — | — | EP | disclosed |
| EP-1140099-A1 | UTILISATION OF 2-SUBSTITUTED 1,2-BENZISOTHIAZOLE DERIVATIVES AND 3-SUBSTITUTED TETRAHYDROPYRIDOPYRIMIDINONE DERIVATIVES FOR THE PROPHYLAXIS AND THERAPY OF CEREBRAL ISCHAEMIA | BASF AKTIENGESELLSCHAFT (DE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000041697-A1 | UTILISATION OF 2-SUBSTITUTED 1,2-BENZISOTHIAZOLE DERIVATIVES AND 3-SUBSTITUTED TETRAHYDROPYRIDOPYRIMIDINONE DERIVATIVES FOR THE PROPHYLAXIS AND THERAPY OF CEREBRAL ISCHAEMIA | BASF AKTIENGESELLSCHAFT (DE) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370990-A1 | TETRAHYDROPYRIDO[4,3-d]PYRIMIDINE INHIBITORS OF ATR KINASE | ATR, DTYMK, CHEK1 | KDM4E 1113/4885ALDH1A1 3090/4885GLA 4296/4885 |
| US-20060258689-A1 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | BDNF, OPRL1, GRIN2D | KDM4E 1876/4885ALDH1A1 1525/4885GLA 1144/4885 |
| US-10421765-B2 | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | ATR, DTYMK, CHEK1 | KDM4E 1113/4885ALDH1A1 3090/4885GLA 4296/4885 |
| US-10745420-B2 | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | ATR, DTYMK, CHEK1 | KDM4E 1113/4885ALDH1A1 3090/4885GLA 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.